Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#354 Risk Stratification Using Octreotide Test For Patients With Gastro-Entero-Pancreatic Neuroendocrine Tumors: Results Of Prospective Validation Of The Test

Introduction: Criteria for treatment with somatostatin analogs (SSAs) of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are presence of somatostatin receptors, a positive Octreoscan® or hormonal decrement >50% after octreotide s.c. injection (octreotide test, OT). We demonstrated that a plasma CgA decrement >/=30% after OT is a selection criterion able to predict the clinical response to SSAs.

Conference:

Presenting Author:

Authors: Rossi R, Massironi S, Spampatti M, Conte D, Ciafardini C,

Keywords: octreotide test, somatostatin analogs,

#305 Risk Stratification Using Octreotide Test for Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results of Prospective Validation of the Test

Introduction: We recently demonstrated that a plasma CgA decrement >30% after octreotide s.c. injection is a simple criterion for treatment with Somatostatin analogues (SSA) of gastroenteropancreatic endocrine tumors.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Massironi S, Spampatti M, Rossi R, Conte D, Ciafardini C,

Keywords: gastroenteropancreatic neuroendocrine tumors (GEP-NETs), octreotide test (OT), prognosis ,

#11 Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Massironi S

Authors: Massironi S, Conte D, Sciola V, Spampatti M, Rossi R,

Keywords: gastroenteropancreatic neuroendocrine tumors, carcinoids, pancreatic endocrine tumors, chromogranin A, somatostatin analogues,